| Qin Li,Xianrong Li,Libo Feng,Xiaolong Chen,Dong Xia,Linxia Xu. Preliminary security investigation and shorttime follow-up of intraoperative intraperitoneal chemotherapy with lobaplatin for advanced colorectal cancer. Oncol Transl Med, 2023, 9: 93-98. |
| 晚期结直肠癌术中洛铂腹腔化疗的初步安全性调查和短期随访 |
| Preliminary security investigation and shorttime follow-up of intraoperative intraperitoneal chemotherapy with lobaplatin for advanced colorectal cancer |
| Received:October 22, 2022 Revised:April 29, 2023 |
| DOI： |
| 中文关键词: 术中腹腔化疗；洛铂；结直肠癌 |
| 英文关键词: intraoperative intraperitoneal chemotherapy; lobaplatin; colorectal cancer |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Qin Li | Southwest Medical University Affiliated Hospital | 253303821@qq.com | | Xianrong Li | Southwest Medical University Affiliated Hospital | | | Libo Feng | Southwest Medical University Affiliated Hospital | | | Xiaolong Chen | Southwest Medical University Affiliated Hospital | | | Dong Xia | Southwest Medical University Affiliated Hospital | | | Linxia Xu* | Southwest Medical University Affiliated Hospital | 14369372@qq.com |
|
| Hits: 3541 |
| Download times: 4540 |
| 中文摘要: |
| 本研究的目的是对晚期结直肠癌术中使用洛铂腹腔化疗进行安全性评估。方法前瞻性地，从2015年2月至2016年2月，选择我科143例结直肠癌手术患者。根据随机表的病例分布情况，将所有患者随机筛选出并纳入腹腔化疗（IPC）组（74例）和对照组（69例）。在试验组中，患者在术中通过腹腔内植入40 mg洛普铂，并在术后采用典型的FOLFOX策略（奥沙利铂、氟尿嘧啶和亚叶酸）进行静脉化疗。对照组仅实施FOLFOX方案。比较肠功能恢复时间、不良反应和并发症，以及化疗前后的实验室检查，并进行为期5年的随访。结果肠功能恢复时间分别为（73.5±9.7）h和（74.8±10.3）h，差异无显著性（P>0.05）。两组均有5例创面脂肪液化（6.8%对7.2%，P>0.05）。恶心和呕吐（57例，77.0%对50例，72.5%）、便秘（43例，58.1%对36例，52.2%）和腹泻（5例，6.8%对5例，7.2%）的结果无统计学意义（均P>0.05）。无论术后还是化疗后，白细胞、血小板和肝肾功能指标均无统计学差异（均P>0.05）。5年生存率无统计学差异（58.1%对56.5%，P>0.05）。结论洛铂术中化疗治疗晚期大肠癌安全、耐受。 |
| 英文摘要: |
| Objective The aim of this study was to conduct a security assessment of intraoperative intraperitoneal
chemotherapy using lobaplatin for advanced colorectal cancer.
Methods From February 2015 to February 2016, 143 patients with colorectal cancer who underwent
surgery in our department were selected prospectively. All patients were randomly screened and enrolled
into the intraperitoneal chemotherapy (IPC) (74 cases) and control (69 cases) groups, depending on the
distribution of cases in the random table. In the trial group, patients were administered 40 mg lobaplatin
by intraperitoneal implantation intraoperatively, together with intravenous chemotherapy post-operatively
using a typical FOLFOX strategy with oxaliplatin, fluorouracil, and leucovorin. In the control group, only
FOLFOX was administered. Bowel function recovery time, adverse reactions and complications, and preand
post-chemotherapy laboratory examinations were compared. In addition, a 5-year-long follow-up was
performed.
Results Recovery times of bowel function were 73.5 ± 9.7 h and 74.8 ± 10.3 h respectively, and the
difference was not significant (P > 0.05). Wound fat liquefaction was observed in five cases in both groups
(6.8% vs. 7.2%, P > 0.05). The outcomes of nausea and vomiting (57 cases, 77.0% vs. 50 cases, 72.5%),
constipation (43 cases, 58.1% vs. 36 cases, 52.2%), and diarrhea (5 cases, 6.8% vs. 5 cases, 7.2%) were not
statistically significant (all P > 0.05). Indices of white blood cell count, blood platelet count, and hepatorenal
function were not significantly different (all P>0.05) neither post-operatively nor post-chemotherapy. The
5-year survival rate was not significantly different between the groups (58.1% vs. 56.5%, P > 0.05).
Conclusion Intraoperative chemotherapy with lobaplatin for advanced colorectal cancer is safe and
tolerable. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|